Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Earnings for Viridian Therapeutics, Inc. (VRDN)
Earnings in 2023 (TTM): $-237,734,000
According to Viridian Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-237,734,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Viridian Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-237,734,000 | $-237,734,000 |
| 2022 | $-129,874,000 | $-125,444,000 |
| 2021 | $-79,413,000 | $-79,416,000 |
| 2020 | $-110,715,000 | $-110,984,000 |
| 2019 | $-41,873,000 | $-42,420,000 |
| 2018 | $-32,703,000 | $-32,703,000 |
| 2017 | $-26,512,000 | $-26,512,000 |
| 2016 | $-12,674,000 | $-12,674,000 |
| 2015 | $-11,328,000 | $-11,328,000 |
| 2014 | $-7,890,000 | $-7,890,000 |
| 2013 | $-2,159,669 | $-2,159,669 |
| 2012 | $-5,618,340 | $-7,211,285 |